Literature DB >> 24057457

Combined 18F-fluoride and 18F-FDG PET/CT: a response based on actual data from prospective studies.

Andrei Iagaru1, Camila Mosci, David W Dick, Mike Sathekge, Paula Lapa, Joao M de Lima, Sanjiv Sam Gambhir.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24057457     DOI： 10.1007/s00259-013-2556-y

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  29 in total

1.  Prospective evaluation of the clinical value of planar bone scans, SPECT, and (18)F-labeled NaF PET in newly diagnosed lung cancer.

Authors:  H Schirrmeister; G Glatting; J Hetzel; K Nüssle; C Arslandemir; A K Buck; K Dziuk; A Gabelmann; S N Reske; M Hetzel
Journal:  J Nucl Med       Date:  2001-12       Impact factor: 10.057

2.  Technical feasibility vs. clinical utility: a question of "can we?" vs. "should we?".

Authors:  Ryan D Niederkohr
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-02       Impact factor: 9.236

Review 3.  Clinical utility of (18)F-fluoride PET/CT in benign and malignant bone diseases.

Authors:  Yuxin Li; Christiaan Schiepers; Ralph Lake; Simin Dadparvar; Gholam R Berenji
Journal:  Bone       Date:  2011-10-06       Impact factor: 4.398

4.  Evaluation of primary prostate cancer using 11C-methionine-PET/CT and 18F-FDG-PET/CT.

Authors:  Masato Shiiba; Keiichi Ishihara; Go Kimura; Tomoyuki Kuwako; Hisashi Yoshihara; Naohisa Yoshihara; Hidetaka Sato; Yukihiro Kondo; Shin-ichi Tsuchiya; Shin-ichiro Kumita
Journal:  Ann Nucl Med       Date:  2011-11-09       Impact factor: 2.668

5.  Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0.

Authors:  Dominique Delbeke; R Edward Coleman; Milton J Guiberteau; Manuel L Brown; Henry D Royal; Barry A Siegel; David W Townsend; Lincoln L Berland; J Anthony Parker; Karl Hubner; Michael G Stabin; George Zubal; Marc Kachelriess; Valerie Cronin; Scott Holbrook
Journal:  J Nucl Med       Date:  2006-05       Impact factor: 10.057

6.  Critical considerations on the combined use of ¹⁸F-FDG and ¹⁸F-fluoride for PET assessment of metastatic bone disease.

Authors:  Gang Cheng; Thomas C Kwee; Sandip Basu; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-05-22       Impact factor: 9.236

7.  Combined 18F-fluoride and 18F-FDG PET/CT scanning for evaluation of malignancy: results of an international multicenter trial.

Authors:  Andrei Iagaru; Erik Mittra; Camila Mosci; David W Dick; Mike Sathekge; Vineet Prakash; Victor Iyer; Paula Lapa; Jorge Isidoro; Joao M de Lima; Sanjiv Sam Gambhir
Journal:  J Nucl Med       Date:  2012-12-14       Impact factor: 10.057

8.  Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: initial results from the National Oncologic PET Registry.

Authors:  Bruce E Hillner; Barry A Siegel; Dawei Liu; Anthony F Shields; Ilana F Gareen; Lucy Hanna; Sharon Hartson Stine; R Edward Coleman
Journal:  J Clin Oncol       Date:  2008-03-24       Impact factor: 44.544

9.  18FDG PET scanning of benign and malignant musculoskeletal lesions.

Authors:  Frieda Feldman; Ronald van Heertum; Chitra Manos
Journal:  Skeletal Radiol       Date:  2003-03-11       Impact factor: 2.199

10.  Combined 18F-Fluoride and 18F-FDG PET/CT scanning for evaluation of malignancy: results of an international multicenter trial.

Authors:  Gary J R Cook
Journal:  J Nucl Med       Date:  2013-01-03       Impact factor: 10.057
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.